This Article Full Text Full Text (PDF) Data Supplement All Versions of this Article: 23/9/1697    most recent 01.ATV.0000087035.46547.89v1 Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Steiner, S. Articles by Kopp, C. W. Search for Related Content PubMed PubMed Citation Articles by Steiner, S. Articles by Kopp, C. W. Related Collections Thrombin Platelets

(Arteriosclerosis, Thrombosis, and Vascular Biology. 2003;23:1697.)
© 2003 American Heart Association, Inc.

Thrombosis

Effect of Glycoprotein IIb/IIIa Antagonist Abciximab on Monocyte-Platelet Aggregates and Tissue Factor Expression

Sabine Steiner; Daniela Seidinger; Kurt Huber; Christoph Kaun; Erich Minar; Christoph W. Kopp

From the Divisions of Angiology (S.S., D.S., E.M., C.W.K.) and Cardiology (K.H., C.K.), 2nd Department of Medicine, University of Vienna, Austria.

Correspondence to Christoph W. Kopp, MD, 2nd Department of Medicine, Division of Angiology, University of Vienna, General Hospital Vienna, Waehringer Guertel 18-20, 1090 Vienna, Austria. E-mail christoph.kopp{at}univie.ac.at

Objective— Activated platelets rapidly adhere to monocytes and upregulate the expression of tissue factor (TF), the major trigger of the coagulation cascade. In this study, we examined the effect of abciximab, a nonselective glycoprotein IIb/IIIa-receptor antagonist, on monocyte TF expression in thrombin receptor activator–stimulated whole blood in vitro.

Methods and Results— Abciximab (50 µg/mL) reduced the mass of platelets attached to monocytes, measured by the mean fluorescence intensity (MFI) of CD42b on CD14⁺ cells, 1 (CD42b, 471±197 versus 1073±217 MFI, mean±SD, P<0.05), 5, and 10 minutes after thrombin receptor activator stimulation of whole blood to the same extent as anti–P-selectin (50 µg/mL; 288±177 MFI, P<0.05) when determined by flow cytometry. In parallel, the expression of the platelet activation marker P-selectin colocalized with CD14⁺ monocytes was reduced up to 25% by abciximab at the same time points. Expression of monocyte TF antigen (CD14⁺/TF⁺, 39.9±8.7% versus 66.3±19.9%, P<0.05), chromogenic TF-activity (TF, 8.4±1.9 versus 13.2±2.8 U, arbitrary units, P<0.05), and TF mRNA was suppressed in the presence of abciximab as a consequence of reduced platelet mass attached to monocytes.

Conclusions— Our data suggest that heterotypic monocyte-platelet aggregates are a target for abciximab, which suppresses monocyte TF because of a reduction of monocyte-platelet cross talk.

Key Words: tissue factor • glycoprotein IIb/IIIa inhibition • abciximab • monocyte-platelet aggregates • flow cytometry

This article has been cited by other articles:

				J. M. van Gils, J. J. Zwaginga, and P. L. Hordijk Molecular and functional interactions among monocytes, platelets, and endothelial cells and their relevance for cardiovascular diseases J. Leukoc. Biol., February 1, 2009; 85(2): 195 - 204. [Abstract] [Full Text] [PDF]

				F. A. Bozza, A. M. Shah, A. S. Weyrich, and G. A. Zimmerman Amicus or Adversary: Platelets in Lung Biology, Acute Injury, and Inflammation Am. J. Respir. Cell Mol. Biol., February 1, 2009; 40(2): 123 - 134. [Abstract] [Full Text] [PDF]

				S. A. Maroney, S. L. Haberichter, P. Friese, M. L. Collins, J. P. Ferrel, G. L. Dale, and A. E. Mast Active tissue factor pathway inhibitor is expressed on the surface of coated platelets Blood, March 1, 2007; 109(5): 1931 - 1937. [Abstract] [Full Text] [PDF]

				Z. Huczek, J. Kochman, K. J. Filipiak, G. J. Horszczaruk, M. Grabowski, R. Piatkowski, J. Wilczynska, A. Zielinski, B. Meier, and G. Opolski Mean Platelet Volume on Admission Predicts Impaired Reperfusion and Long-Term Mortality in Acute Myocardial Infarction Treated With Primary Percutaneous Coronary Intervention J. Am. Coll. Cardiol., July 19, 2005; 46(2): 284 - 290. [Abstract] [Full Text] [PDF]

				S. Steiner, W. S. Speidl, J. Pleiner, D. Seidinger, G. Zorn, C. Kaun, J. Wojta, K. Huber, E. Minar, M. Wolzt, et al. Simvastatin Blunts Endotoxin-Induced Tissue Factor In Vivo Circulation, April 12, 2005; 111(14): 1841 - 1846. [Abstract] [Full Text] [PDF]

				A. Straub, H. P. Wendel, R. Azevedo, and G. Ziemer The GP IIb/IIIa inhibitor abciximab (ReoPro(R)) decreases activation and interaction of platelets and leukocytes during in vitro cardiopulmonary bypass simulation Eur. J. Cardiothorac. Surg., April 1, 2005; 27(4): 617 - 621. [Abstract] [Full Text] [PDF]

				P. R. Moreno and V. Fuster The year in atherothrombosis J. Am. Coll. Cardiol., December 7, 2004; 44(11): 2099 - 2110. [Full Text] [PDF]

				T. Palmerini, B. S. Coller, V. Cervi, L. Tomasi, A. Marzocchi, C. Marrozzini, O. Leone, M. Piccioli, and A. Branzi Monocyte-derived tissue factor contributes to stent thrombosis in an in vitro system J. Am. Coll. Cardiol., October 19, 2004; 44(8): 1570 - 1577. [Abstract] [Full Text] [PDF]

				S. Steiner-Boker, M. Cejna, C. Nasel, E. Minar, and C. W. Kopp Successful Revascularization of Acute Carotid Stent Thrombosis by Facilitated Thrombolysis AJNR Am. J. Neuroradiol., September 1, 2004; 25(8): 1411 - 1413. [Abstract] [Full Text] [PDF]